Esperion Therapeutics Inc
Research Esperion Therapeutics Inc (ESPR) on Bullrun: market cap USD 818.63M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerESPR
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 818.63M
- Financial periodQ1 2026
- RevenueUSD 80.10M
- Net income-USD 25.20M
- Free cash flow-USD 27.91M
- Gross margin56.8%
Valuation Snapshot
latest market cap is USD 818.63M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 403.14M | -USD 22.68M | -USD 13.09M | 67.9% | -0.11 | USD 167.85M | USD 252.23M | -USD 301.97M |
| FY2024 | USD 332.31M | -USD 51.75M | -USD 23.97M | 79.4% | -0.28 | USD 144.76M | USD 297.60M | -USD 388.72M |
| FY2023 | USD 116.33M | -USD 209.25M | -USD 135.49M | n/a | -2.03 | USD 82.25M | USD 266.17M | -USD 454.99M |
| FY2022 | USD 75.48M | -USD 233.66M | -USD 174.83M | n/a | -3.52 | USD 124.78M | USD 260.17M | -USD 323.78M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-07-14 | USD 818.63M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 907.30M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 430.88M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 340.02M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 459.05M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 304.40M | n/a | n/a | n/a |
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Esperion Therapeutics Inc's market cap?
Esperion Therapeutics Inc's market capitalization is USD 818.63M.
What does Esperion Therapeutics Inc do?
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C.